Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Samar Kulkarni, Adrian Bloor, Mike Dennis, Anna Z Castleton, Mark Williams, Ahmed Abdulgawad, Tim Somervaille, Daniel H Wiseman, Vismay Deshani, Emma Searle, Angie Leather, John Murray, Sally Pickering, James Cavet

Blood (2024) 144 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2024-211021

Published: 2024

Journal Articles

Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

Vismay Deshani, H Hemat, Adrian Bloor, Mike Dennis, Alex Peel, Adam Jeans, Anna Z Castleton, Emma Searle, Daniel H Wiseman, Mark Williams, Richard Chasty, Ahmed Abdulgawad, Tim Somervaille, John Murray, Jane Robertson, James Cavet, Samar Kulkarni

Blood (2024) 144 (Supplement 1): 7897.

https://doi.org/10.1182/blood-2024-198526

Published: 2024

Journal Articles

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Blood (2024) 144 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2024-207251

Published: 2024

Journal Articles

Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Emma Searle, Victoria Campbell, Charlotte Pawlyn, Ceri Bygrave, Sarah Gooding, James Cavet, Matthew W. Jenner, Vivek Radhakrishnan, Steve Knapper, Dima el-Sharkawi, Jenny O'Nions, Tomasz Knurowski, Karen Clegg, Will Henry West, Debbie Haynes, Kris Frese, Tim Somervaille

Blood (2024) 144 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2024-199779

Published: 2024

Journal Articles

Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma

Victoria Campbell, Harriet Walter, Adam Gibb, Andrew S. Davies, Nagah Elmusharaf, Neil Pegg, Will Henry West, Tomasz Knurowski, Kris Frese, Debbie Haynes, Karen Clegg, Tim Somervaille

Blood (2023) 142 (Supplement 1): 5795.

https://doi.org/10.1182/blood-2023-187378

Published: 2023

Journal Articles

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2023-174652

Published: 2023

Journal Articles

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Adam J. Mead, MD PhD, Tim Somervaille, Professor, MD, Nauman M Butt, MD, Waseem Nagi, MD FRCPath, Alastair J Whiteway, MBBS, Suriya Kirkpatrick, MD, Ciro R Rinaldi, MD PhD, Catherine Roughley, MD, Sam Ackroyd, MD, Joanne Ewing, PhDBMBS BSc FRPATH, Pratap Neelakantan, MD FRCPath, Mamta Garg, MD FRCP, FRCPath, Claire N Harrison, Professor, David Tucker, MD, Rozinder Bains, Gavin Chiu, MBBS, MRCGP, MFPM, DPM, BSc, Joe Hickey, PhD

Blood (2019) 134 (Supplement_1): 1671.

https://doi.org/10.1182/blood-2019-124686

Published: 2019

Journal Articles

Post Allograft Rituximab Responsive Cytopenia (RRC)

Samar Kulkarni, MD, John Murray, RGN, MSc, David Kaye, MSc, Michael Dennis, FRCPath, Anna Castleton, FRCPath, Mohd K Mamat, MRCP, James Cavet, Daniel Wiseman, FRCPath, Tim Somervaille, FRCPath, Sven Sommerfeld, MRCP, Richard Chasty, FRCPath, Adrian Bloor, FRCPath

Blood (2019) 134 (Supplement_1): 5645.

https://doi.org/10.1182/blood-2019-132214

Published: 2019

Journal Articles

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Andreas Reiter, MD, Gunay Ahmadova, MD, Mohamad Jawhar, MD, Andres Virchis, MD, Tim Somervaille, MDPhD, Mark Williams, MD, Bernd Schönberger, MD, Rebecca Frewin, FRCPath, MRCP, MBBS, BSc, Philipp J. Jost, MD, Annett Maschke, MD, Peter Keller, MD, Torsten Haferlach, MD, Nicole Naumann, Juliana Schwaab, MD, Alice Fabarius, PhD, Wolf-Karsten Hofmann, MD, Claudia Haferlach, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD

Blood (2016) 128 (22): 3114.

https://doi.org/10.1182/blood.V128.22.3114.3114

Published: 2016

Journal Articles

Therapeutic Cyclosporine Exposure Measured As Area Under the Curve (AUC) Significantly Influences the Outcome after Allogeneic Hematopoetic Stem Cell Transplant (alloHSCT)

Samar Kulkarni, MD MRCP, FRCPath, John Murray, BSc (hons), MSc, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Anna Z Castleton, FRCPath, Tim Somervaille, MDPhD, Daniel Wiseman, FRCPath, Joanna Tomlins, MSc, Adrian Bloor

Blood (2016) 128 (22): 2237.

https://doi.org/10.1182/blood.V128.22.2237.2237

Published: 2016

Journal Articles

Retrospective Analysis of Seasonal Respiratory Viral Infections (SRVI) in Hematology, Lymphoma and Oncology Patients

Samar Kulkarni, MD MRCP, FRCPath, Stephanie Michail, MBBS, Charlotte Smith, MSc, Joanna Tomlins, MSc, John Murray, BSc (hons), MSc, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, MD PhD, Daniel Wiseman, FRCPath, Anna Z Castleton, FRCPath, Adrian Bloor

Blood (2016) 128 (22): 4608.

https://doi.org/10.1182/blood.V128.22.4608.4608

Published: 2016

Journal Articles

Higher Incidence and Risk of Developing Second Solid Cancers (SSC) after Haematopoetic Stem Cell Transplantation (HSCT) As Compared to General Population

Samar Kulkarni, MD MRCP, FRCPath, John Murray, BSc (hons), MSc, Charlotte Smith, MSc, Stephanie Cleaver, RGN, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, MD PhD, Anna Z Castleton, FRCPath, Daniel Wiseman, FRCPath, Joanna Tomlins, MSc, Kaz Mamat, MRCP, Angie Leather, MSc, Rita Angelica, BSc, Adrian Bloor

Blood (2016) 128 (22): 4610.

https://doi.org/10.1182/blood.V128.22.4610.4610

Published: 2016

Journal Articles

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Tim Somervaille, MD PhD, Olga Salamero, MD, Pau Montesinos, MD PhD, Christophe Willekens, MD, Jose Antonio Perez Simon, MD, Arnaud Pigneux, MD, Christian Recher, MD PhD, Rakesh Popat, Cesar Molinero, MD PhD, Christina Mascaro, PhD, Tamara Maes, PhD, Francesc Bosch, MD PhD

Blood (2016) 128 (22): 4060.

https://doi.org/10.1182/blood.V128.22.4060.4060

Published: 2016

Journal Articles

Use of CMV Unselected Blood Products Does Not Increase the Risk of CMV Reactivation in Patients Undergoing Hematopoetic Stem Cell Transplant (HSCT)

Jayne Peters, MRCP, Jonathon Elliott, MRCP, Adrian Bloor, FRCPath, Michael Dennis, FRCPath, John Murray, MSc, Jim Cavet, FRCPath, Tim Somervaille, Sven Armin Sommerfeld, MRCP, Ken Mutton, FRCPath, Kaz Mamat, MRCP, Malcolm Guiver, PhD, Samar Kulkarni, FRCPath

Blood (2015) 126 (23): 2346.

https://doi.org/10.1182/blood.V126.23.2346.2346

Published: 2015

Journal Articles

Incidence of Thrombotic Complications with Use of Peg-Asparginase in Treatment for Acute Lymphoblastic Leukemia (ALL) in Adults and Young Adolescent Patients

David JM Routledge, MRCP, Joanna Tomlins, MSc, Adrian Bloor, FRCPath, Kaz Mamat, MRCP, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, Sven Armin Sommerfeld, MRCP, Samar Kulkarni, FRCPath

Blood (2015) 126 (23): 4864.

https://doi.org/10.1182/blood.V126.23.4864.4864

Published: 2015

Journal Articles

Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Alessandro M. Vannucchi, Ruben A. Mesa, Francisco Cervantes, Ritam Prasad, Janos Jakucs, Anna Elinder, Christian Recher, MDPhD, Peter A. te Boekhorst, Steven Knapper, Tim Somervaille, James P. Dean, Tanya Granston, Adam Mead, Claire N. Harrison

Blood (2015) 126 (23): 58.

https://doi.org/10.1182/blood.V126.23.58.58

Published: 2015

Journal Articles

Population Based Study of Cytogenetic Abnormalities in Addition to Philadelphia (Ph) Chromosome in Patients with Chronic Myeloid Leukaemia (CML) and Impact on Survival

Jo Tomlins, MSc, Nick Telford, PhD, Mike Dennis, FRCPath, Tim Somervaille, FRCPath, Adrian Bloor, PhD FRCPath, Jim Cavet, FRCPath, Mike Green, PhD, Sven Armin Sommerfeld, MRCP, John Murray, RGN, MSc, Samar Kulkarni, FRCPath

Blood (2014) 124 (21): 4567.

https://doi.org/10.1182/blood.V124.21.4567.4567

Published: 2014

Journal Articles

Advanced Age at Transplant Increases the Risk of Second Solid Malignancy (SSM) after Haematopoetic Stem Cell Transplantation (HSCT)

John Murray, RGN, MSc, John Chadwick, MRCP, Adrian Bloor, PhD FRCPath, Jim Cavet, FRCPath, Mike Dennis, FRCPath, Tim Somervaille, FRCPath, Sven Armin Sommerfeld, MRCP, John Eliott, MRCP, Siobhan Muthia, MRCP, Angie Leather, RGN BSc, Rita Angelica, RGN BSc, Rachel Brown, MRCP, Jo Tomlins, MSc, Samar Kulkarni, FRCPath

Blood (2014) 124 (21): 3952.

https://doi.org/10.1182/blood.V124.21.3952.3952

Published: 2014

Journal Articles

Enhancers of Polycomb EPC1 and EPC2 Prevent Accumulation of MYC to Sustain the Oncogenic Potential of MLL Leukemia Stem Cells

Xu Huang, PhD, Tim Somervaille, PhD MRCP FRCPath

Blood (2012) 120 (21): 400.

https://doi.org/10.1182/blood.V120.21.400.400

Published: 2012

Journal Articles

TTC5, a TPR Motif Cofactor Protein Required for Myeloid Leukaemogenesis

James T Lynch, PhD, Tim Somervaille, PhD MRCP FRCPath

Blood (2011) 118 (21): 59.

https://doi.org/10.1182/blood.V118.21.59.59

Published: 2011

NARROW

Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Post Allograft Rituximab Responsive Cytopenia (RRC)

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Therapeutic Cyclosporine Exposure Measured As Area Under the Curve (AUC) Significantly Influences the Outcome after Allogeneic Hematopoetic Stem Cell Transplant (alloHSCT)

Retrospective Analysis of Seasonal Respiratory Viral Infections (SRVI) in Hematology, Lymphoma and Oncology Patients

Higher Incidence and Risk of Developing Second Solid Cancers (SSC) after Haematopoetic Stem Cell Transplantation (HSCT) As Compared to General Population

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Use of CMV Unselected Blood Products Does Not Increase the Risk of CMV Reactivation in Patients Undergoing Hematopoetic Stem Cell Transplant (HSCT)

Incidence of Thrombotic Complications with Use of Peg-Asparginase in Treatment for Acute Lymphoblastic Leukemia (ALL) in Adults and Young Adolescent Patients

Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Population Based Study of Cytogenetic Abnormalities in Addition to Philadelphia (Ph) Chromosome in Patients with Chronic Myeloid Leukaemia (CML) and Impact on Survival

Advanced Age at Transplant Increases the Risk of Second Solid Malignancy (SSM) after Haematopoetic Stem Cell Transplantation (HSCT)

Enhancers of Polycomb EPC1 and EPC2 Prevent Accumulation of MYC to Sustain the Oncogenic Potential of MLL Leukemia Stem Cells

TTC5, a TPR Motif Cofactor Protein Required for Myeloid Leukaemogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only